Ferric carboxymaltose with or without erythropoietin for the prevention of red-cell transfusions in the perioperative period of osteoporotic hip fractures: a randomized contolled trial. The PAHFRAC-01 project

Table 2 The three treatment arms of the PAHFRAC-01 clinical trial

TREATMENT ARM	TREATMENT DESCRIPTION
EPOFE ARM	Single dose of 40.000 IU of erythropoietin in a pre-filled 1 ml syringe, subcutaneously. Ferric carboxymaltose 1000 mg (two 500 mg vials diluted in a bottle of 250 ml of saline, in a plastic bag, and with an opaque infusion system), intravenously in a 20-min infusion.
FE ARM	Single dose placebo (saline) in a pre-filled 1 ml syringe, subcutaneously. Ferric carboxymaltose 1000 mg (two 500 mg vials diluted in a bottle of 250 ml of saline, in a plastic bag, and with an opaque infusion system), intravenously in a 20-min infusion.
PLACEBO ARM	Single dose placebo (saline) in a pre-filled 1 ml syringe, subcutaneously. Ferric carboxymaltose 1000 mg (two 500 mg vials diluted in a bottle of 250 ml of saline, in a plastic bag, and with an opaque infusion system), intravenously in a 20-min infusion.

ISSN: 1471-2474